# An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy

> **NCT06288230** · PHASE1,PHASE2 · RECRUITING · sponsor: **Lantu Biopharma** · enrollment: 20 (estimated)

## Conditions studied

- Spinal Muscular Atrophy

## Interventions

- **BIOLOGICAL:** vesemnogene lantuparvovec

## Key facts

- **NCT ID:** NCT06288230
- **Lead sponsor:** Lantu Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06288230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06288230, "An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06288230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*